Emisphere’s Oral Insulin Candidate
Delivers unaltered insulin
No membrane permeablizers
Favorable kinetics consistently demonstrated
Carrier manufacturing scaled up
Carrier safety demonstrated in 90-day primate studies
Pursue Type I and Type II therapy